JPMorgan Chase & Co. Has $5.70 Million Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

JPMorgan Chase & Co. decreased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 71.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 153,571 shares of the company's stock after selling 385,349 shares during the period. JPMorgan Chase & Co. owned 0.32% of Amphastar Pharmaceuticals worth $5,702,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its stake in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after purchasing an additional 493 shares during the period. Parkside Financial Bank & Trust lifted its holdings in Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after purchasing an additional 871 shares during the period. TD Private Client Wealth LLC raised its position in shares of Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after buying an additional 388 shares in the last quarter. KBC Group NV raised its holdings in Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock worth $80,000 after purchasing an additional 650 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Amphastar Pharmaceuticals by 90.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company's stock valued at $156,000 after purchasing an additional 1,992 shares during the period. Institutional investors and hedge funds own 65.09% of the company's stock.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 27.10% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Stock Up 1.3 %

NASDAQ:AMPH traded up $0.32 on Thursday, hitting $23.88. 68,058 shares of the company's stock traded hands, compared to its average volume of 462,694. The firm has a 50-day moving average price of $27.31 and a 200-day moving average price of $36.88. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company has a market cap of $1.13 billion, a PE ratio of 7.96, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 1 year low of $22.64 and a 1 year high of $53.96.

Analyst Ratings Changes

A number of brokerages recently weighed in on AMPH. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Piper Sandler reduced their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.